These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 20101733)

  • 1. Prostate cancer treatment for economically disadvantaged men: a comparison of county hospitals and private providers.
    Parsons JK; Kwan L; Connor SE; Miller DC; Litwin MS
    Cancer; 2010 Mar; 116(5):1378-84. PubMed ID: 20101733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of prostate carcinoma care in a statewide public assistance program.
    Krupski TL; Bergman J; Kwan L; Litwin MS
    Cancer; 2005 Sep; 104(5):985-92. PubMed ID: 16047332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above.
    Kupelian PA; Buchsbaum JC; Elshaikh M; Reddy CA; Zippe C; Klein EA
    Cancer; 2002 Dec; 95(11):2302-7. PubMed ID: 12436435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate brachytherapy: a descriptive analysis from CaPSURE.
    Lee WR; Sharkey J; Cowan JE; DuChane J; Carroll PR;
    Brachytherapy; 2007; 6(2):123-8. PubMed ID: 17434105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 1999 patterns of care study of radiotherapy in localized prostate carcinoma: a comprehensive survey of prostate brachytherapy in the United States.
    Lee WR; Moughan J; Owen JB; Zelefsky MJ
    Cancer; 2003 Nov; 98(9):1987-94. PubMed ID: 14584083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer: socio-economic, geographical and private-health insurance effects on care and survival.
    Hall SE; Holman CD; Wisniewski ZS; Semmens J
    BJU Int; 2005 Jan; 95(1):51-8. PubMed ID: 15638894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Race as an independent predictor of outcome after treatment for localized prostate cancer.
    Sohayda CJ; Kupelian PA; Altsman KA; Klein EA
    J Urol; 1999 Oct; 162(4):1331-6. PubMed ID: 10492191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment choice and quality of care for men with localized prostate cancer.
    Miller DC; Spencer BA; Ritchey J; Stewart AK; Dunn RL; Sandler HM; Wei JT; Litwin MS
    Med Care; 2007 May; 45(5):401-9. PubMed ID: 17446826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health-insurance status is a determinant of the stage at presentation and of cancer control in European men treated with radical prostatectomy for clinically localized prostate cancer.
    Gallina A; Karakiewicz PI; Chun FK; Briganti A; Graefen M; Montorsi F; Walz J; Jeldres C; Erbersdobler A; Salonia A; Suardi N; Dehò F; Schlomm T; Scattoni V; Haese A; Heinzer H; Valiquette L; Rigatti P; Huland H
    BJU Int; 2007 Jun; 99(6):1404-8. PubMed ID: 17428250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of treatment regret in low-income, uninsured men with prostate cancer.
    Hu JC; Kwan L; Krupski TL; Anger JT; Maliski SL; Connor S; Litwin MS
    Urology; 2008 Dec; 72(6):1274-9. PubMed ID: 18313115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials.
    Nanda A; Chen MH; Renshaw AA; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1419-23. PubMed ID: 19131185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediagnostic prostate-specific antigen velocity and probability of detecting high-grade prostate cancer.
    Krejcarek SC; Chen MH; Renshaw AA; Loffredo M; Sussman B; D'Amico AV
    Urology; 2007 Mar; 69(3):515-9. PubMed ID: 17382156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE).
    Meng MV; Elkin EP; Latini DM; Duchane J; Carroll PR
    J Urol; 2005 May; 173(5):1557-61. PubMed ID: 15821485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Body mass index and prostate-specific antigen failure following brachytherapy for localized prostate cancer.
    Efstathiou JA; Skowronski RY; Coen JJ; Grocela JA; Hirsch AE; Zietman AL
    Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1302-8. PubMed ID: 18262732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy.
    Palma D; Tyldesley S; Pickles T;
    Cancer; 2008 May; 112(9):1941-8. PubMed ID: 18338814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mortality in men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapy.
    Dosoretz AM; Chen MH; Salenius SA; Ross RH; Dosoretz DE; Katin MJ; Mantz C; Nakfoor BM; D'Amico AV
    Cancer; 2010 Feb; 116(4):837-42. PubMed ID: 20052734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer.
    Tsai HK; Chen MH; McLeod DG; Carroll PR; Richie JP; D'Amico AV
    Cancer; 2006 Dec; 107(11):2597-603. PubMed ID: 17039498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.